市场调查报告书
商品编码
1416202
药物洗脱球囊导管市场规模-按产品[冠状动脉和周围血管疾病导管(紫杉醇、西罗莫司)]、材料(聚氨酯、尼龙)、最终用途和全球预测,2023-2032 年Drug-eluting Balloon Catheters Market Size - By Product [Coronary Artery & Peripheral Vascular Disease Catheters (Paclitaxel, Sirolimus)], Material (Polyurethane, Nylon), End-use & Global Forecast, 2023-2032 |
药物洗脱球囊导管市场预计从 2023 年到 2032 年将以 11.5% 的CAGR扩张。全球心血管疾病盛行率不断上升,对有效治疗方案的需求不断增加。
医疗技术的不断进步和创新导管设计的发展正在提高药物洗脱球囊手术的功效,吸引了患者和医疗保健提供者。例如,2022 年 5 月,美敦力 (Medtronic) 的 IN 获得 FDA 批准。 PACT 018 紫杉醇涂层 PTA 球囊导管,一种药物涂层球囊 (DCB),用于介入治疗股浅动脉和腘动脉周围动脉疾病 (PAD)。此外,人口老化的加剧导致冠状动脉疾病的发生率增加,进一步刺激了药物洗脱球囊导管的需求。此外,有利报销政策的涌入以及政府支持采用先进医疗设备的倡议的增加将推动市场成长。
药物洗脱球囊导管市场按产品、材料、最终用途和地区划分。
根据产品,冠状动脉疾病药物洗脱球囊导管领域的市场价值预计在 2023 年至 2032 年间将以 11.8% 的CAGR增长。这一增长可归因于冠状动脉疾病患病率的增加和导管技术的不断进步。对微创治疗方案的需求不断增加也将推动该细分市场的成长。
预计 2023 年至 2032 年,尼龙材料领域的药物洗脱球囊导管市场份额复合CAGR为 11.4%。这是由于尼龙为导管结构提供了有利的特性,包括灵活性和耐用性。此外,尼龙的生物相容性及其在血管成形术过程中有效输送药物的能力将增强药物洗脱球囊导管的整体性能。
从区域来看,亚太地区药物洗脱球囊导管产业规模预计从 2023 年到 2032 年将以 14.6% 的CAGR扩大。这种增长可归因于心血管疾病盛行率的不断上升、对微创治疗方案的认识不断提高以及完善的微创治疗方案。医疗保健基础设施。不断扩大的患者群体导致人们越来越关注改善医疗保健的可近性。此外,医疗技术的不断进步和政府的有利措施将加速区域产品需求。
Drug-eluting balloon catheters market is projected to expand at 11.5% CAGR from 2023 to 2032. The rising prevalence of cardiovascular diseases across the globe is escalating the demand for effective treatment options.
The rising advancements in medical technologies and the development of innovative catheter designs is enhancing the efficacy of drug-eluting balloon procedures, attracting both patients and healthcare providers. For instance, in May 2022, Medtronic received the FDA approval for the IN. PACT 018 Paclitaxel-Coated PTA balloon catheter, a drug-coated balloon (DCB) for interventional treatment of peripheral arterial disease (PAD) in the superficial femoral and popliteal arteries. Additionally, the growing aging population is contributing to the increased incidences of coronary artery diseases, further fueling the demand for drug-eluting balloon catheters. Moreover, the influx of favorable reimbursement policies and the rise in government initiatives for supporting the adoption of advanced medical devices will boost the market growth.
The drug-eluting balloon catheters market is segregated into product, material, end-use, and region.
Based on product, the market value from the coronary artery disease drug eluting balloon catheters segment is projected to rise at 11.8% CAGR between 2023 to 2032. The growth can be attributed to the increasing prevalence of coronary artery diseases and the rising advancements in catheter technologies. The heightening demand for minimally invasive treatment options will also drive the segment growth.
Drug-eluting balloon catheters market share from the nylon material segment is estimated to witness 11.4% CAGR from 2023 to 2032. This is due to the favorable properties offered by nylon for catheter construction, including flexibility and durability. Moreover, the biocompatibility of nylon coupled with its ability to effectively deliver drugs during angioplasty procedures will enhance the overall performance of drug-eluting balloon catheters.
Regionally, the Asia Pacific drug eluting balloon catheter industry size is projected to expand at 14.6% CAGR from 2023 to 2032. The growth can be attributed to the growing prevalence of cardiovascular diseases, increasing awareness about minimally invasive treatment options, and the well-established healthcare infrastructure. The expanding patient pool is leading to the growing focus on improving healthcare accessibility. Additionally, the rising advancements in medical technologies and favorable government initiatives will accelerate the regional product demand.